ESR2 and cancer: However, it has been reported that the risk of estrogen-dependent cancer, including ovarian and womb cancer, increases in patients who have received such hormonal therapy because synthetic estrogen binds to estrogen receptor (ER) α with higher affinity than ERβ [[58], [59], [60]].